NanoVibronix Files Q2 2024 10-Q

TL;DR

NanoVibronix dropped its Q2 10-Q. Check financials.

AI Summary

NanoVibronix, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported its financial results for the second quarter and the first six months of 2024. Specific financial figures for revenue, net income/loss, and cash flow are detailed within the filing, reflecting the company's operational and financial performance during this period.

Why It Matters

This filing provides investors with the latest financial performance data for NanoVibronix, Inc., crucial for understanding the company's current health and future prospects.

Risk Assessment

Risk Level: medium — As a publicly traded company, NanoVibronix is subject to market fluctuations and regulatory requirements, making its risk profile inherently medium.

Key Numbers

• 20240630 — Reporting Period End Date (Indicates the end of the fiscal quarter for which financial data is reported.)
• 20240814 — Filing Date (The date the 10-Q was officially submitted to the SEC.)

Key Players & Entities

• NanoVibronix, Inc. (company) — Filer of the 10-Q
• 20240630 (date) — End of reporting period
• 20240814 (date) — Filing date
• Elmsford, NY (location) — Company's business and mailing address

FAQ

Key Financial Figures

• $0.001 — ch registered Common Stock, par value $0.001 per share NAOV NASDAQ Capital Mark

Filing Documents

• form10-q.htm (10-Q) — 780KB
• ex31-1.htm (EX-31.1) — 18KB
• ex31-2.htm (EX-31.2) — 18KB
• ex32-1.htm (EX-32.1) — 6KB
• ex32-2.htm (EX-32.2) — 6KB
• form10-q_001.jpg (GRAPHIC) — 24KB
• 0001493152-24-032138.txt ( ) — 4037KB
• naov-20240630.xsd (EX-101.SCH) — 27KB
• naov-20240630_cal.xml (EX-101.CAL) — 46KB
• naov-20240630_def.xml (EX-101.DEF) — 137KB
• naov-20240630_lab.xml (EX-101.LAB) — 257KB
• naov-20240630_pre.xml (EX-101.PRE) — 206KB
• form10-q_htm.xml (XML) — 534KB

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION Item 1.

Financial Statements (Unaudited)

Financial Statements (Unaudited) 1 Condensed Consolidated Balance Sheets as of June 30, 2024 (Unaudited) and December 31, 2023 1 Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss for the Three and Six Months Ended June 30, 2024 and 2023 2 Unaudited Condensed Consolidated Statements of Stockholders' Equity for the Three and Six Months Ended June 30, 2024 and 2023 3 Unaudited Condensed Consolidated Statements of Cash Flows for the Three and Six months Ended June 30, 2024 and 2023 4 Notes to Unaudited Condensed Consolidated Financial Statements 5 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 13 Item 3.

Quantitative and Qualitative Disclosures about Market Risk

Quantitative and Qualitative Disclosures about Market Risk 19 Item 4.

Controls and Procedures

Controls and Procedures 19

OTHER INFORMATION

PART II. OTHER INFORMATION Item 1.

Legal Proceedings

Legal Proceedings 20 Item 1A.

Risk Factors

Risk Factors 21 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 23 Item 3. Defaults Upon Senior Securities 23 Item 4. Mine Safety Disclosures 23 Item 5. Other Information 23 Item 6. Exhibits 24

Signatures

Signatures 25 i PART I - FINANCIAL INFORMATION ITEM 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS NanoVibronix, Inc. Condensed Consolidated Balance Sheets (Amounts in thousands except share and per share data) (Unaudited) June 30, 2024 December 31, 2023 ASSETS: Current assets: Cash $ 2,170 $ 3,283 Trade receivables 489 318 Prepaid expenses and other accounts receivable 296 154 Inventory 2,431 2,732 Total current assets 5,386 6,487 Noncurrent assets: Fixed assets, net 9 7 Other assets 1 1 Severance pay fund 167 174 Operating lease right-of-use assets, net 133 5 Total non-current assets 310 187 Total assets $ 5,696 $ 6,674 LIABILITIES AND STOCKHOLDERS' EQUITY: Current liabilities: Trade payables $ 92 $ 138 Other accounts payable and accrued expenses 2,383 2,265 Deferred licensing income, current 37 46 Operating lease liabilities, current 44 5 Total current liabilities 2,556 2,454 Non-current liabilities: Accrued severance pay 209 217 Deferred licensing income, non-current 1 15 Operating lease liabilities, non-current 89 - Total liabilities 2,855 2,686 Commitments and contingencies - Stockholders' equity: - Series C Preferred Stock of $ 0.001 par value – Authorized: 3,000,000 shares at both June 30, 2024 and December 31, 2023; issued and outstanding: 0 shares at both June 30, 2024 and December 31, 2023, respectively - - Series D Preferred Stock of $ 0.001 par value – Authorized: 506 shares at both June 30, 2024, and December 31, 2023; issued and outstanding: 0 shares at both June 30, 2024 and December 31, 2023, respectively - - Series E Preferred Stock of $ 0.001 par value – Authorized: 1,999,494 shares at both June 30, 2024 and December 31, 2023, respectively; issued and outstanding: 0 shares at both June 30, 2024 and December 31, 2023, respectively - - Series F Preferred Stock of $ 0.01 par value – Authorized: 40,000 and 0 shares at Jun

View Full Filing

View this 10-Q filing on SEC EDGAR